Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY

NCT ID: NCT03419000

Last Updated: 2025-09-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-16
• Study Completion Date: 2022-03-31

Brief Summary

Sudden and unexpected death in epilepsy (SUDEP) has become a major issue for patients with epilepsy and their physicians. SUDEP is a nontraumatic and non-drowning death in patients with epilepsy, unrelated to a documented status epilepticus, in which postmortem examination does not reveal a toxicologic or anatomic cause of death. It primarily affects young adults with drug-resistant epilepsy, with an incidence of about 0.5%/year. A recent study reported that up to 20% of patients with childhood onset drug resistant epilepsy will die of a SUDEP by the age of 45. Apart from optimizing antiepileptic drugs, no preventive treatment is available to prevent SUDEP. As underscored by the World Health Organization (WHO), there is an urgent need to develop specific therapeutic approaches to tackle this issue.

The primary objective of the proposal is to evaluate the diagnostic value of a set of circulating microRNAs pre-selected because of their implication in the regulation of molecular pathways involved in the respiratory regulation to identify patients with seizure-related respiratory dysfunction, as defined by occurrence ictal/peri-ictal pulse oxymetry < 90%.

A total of 50 patients will be included over a period of one year. Patients undergoing long-term video-EEG/SEEG monitoring will be recruited in the epilepsy monitoring unit of the Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon, France.

It will be a case-control study in a cohort of patients with drug-resistant focal epilepsy undergoing long-term video-EEG monitoring, in which patients who demonstrate ictal/post-ictal hypoxemia (cases) will be compared with those without seizure-related respiratory dysfunction (controls).

Conditions

Drug Resistant Epilepsy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patient

Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure

Group Type: EXPERIMENTAL

blood sample

Intervention Type: GENETIC

Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes

healthy volunteers

Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders

Group Type: ACTIVE_COMPARATOR

blood sample

Intervention Type: GENETIC

Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes

Interventions

blood sample

Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

For the patients :

• Adult patient (≥ 18 years) suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification
• Patient undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
• Patient who gave her/his written informed consent to participate to the study
• Patient affiliated to the French health care system

For the healthy volunteers :

• Adult (≥ 18 years)
• Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
• Subject who gave her/his written informed consent to participate to the study
• Subject affiliated to the French health care system

Exclusion Criteria

For the patients :

• Ongoing major depressive episode as defined by a score ≥ 15 at the French version of the NDDI-E scale*
• Current panic disorder as defined by a score ≥ 7 at the French version of the GAD-7 scale*
• Ongoing treatment with selective serotonin reuptake inhibitor
• Patient who benefit from a protective measure

For the healthy volunteers :

• Presence of the symptoms of anxiety and/or depression as defined by a score ≥ 11 at the French version of the Hospital Anxiety and Depression Scale (HADS)
• Ongoing treatment with selective serotonin reuptake inhibitor
• Subjects with these psychiatric comorbidities and/or treatment will be excluded in order to limit risk that the relation previously reported between miR-135a, miR-16, miR-1202 and depression and/or panic disorder and/or response to selective serotonin

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sylvain RHEIMS

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon

Locations

Hospices Civils de Lyon

Bron, , France

Service de Neurophysiologie Clinique Hôpital La Timone

Marseille, , France

Countries

France

Other Identifiers

2017-A03307-46

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL17_0666

Identifier Type: -

Identifier Source: org_study_id